MNKD Snapshot del titolo Prezzo, capitalizzazione di mercato, P/E, EPS, ROE, debito/capitale proprio, intervallo 52 settimane

03

Prezzo $3.82

Capitalizzazione di Mercato (MRQ) $1.18B

P/E (TTM) -29.4

EPS (TTM) $-0.13

Ricavi (TTM) $394M

ROE (TTM) 71.4%

Intervallo 52 sett. $2–$7

MNKD Grafico del prezzo delle azioni OHLCV giornaliero con indicatori tecnici — panoramica, zoom e personalizza la tua visualizzazione

04

intervallo

barre

La granularità delle barre si adatta al periodo selezionato — passa il mouse sul grafico per vedere apertura/massimo/minimo/chiusura di una barra.

Split azionari 1

Data ex-dividendo	Split	Tipo
03 Marzo 2017	1-for-5	Inverso

Informazioni su MannKind Corporation - Common Stock Panoramica della società da Wikipedia

05 · wikidata

MannKind Corporation is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. Based in Danbury, Connecticut, the company was founded in February 1991.

MannKind Corporation was named after its founder, Alfred E. Mann.

History

Founded in February 1991, the company's present form is a result of a 2003 merger of three companies owned by Alfred E. Mann: Pharmaceutical Discovery Corporation (PDC), the cancer vaccine developer CTL ImmunoTherapies, Inc., and its sister company Allecure Corp, which was developing an allergy vaccine technology. Pharmaceutical Discovery was purchased in 2001 from Solomon Steiner; with that purchase MannKind acquired the Technosphere molecule and Medtone inhaler, upon which was developed its lead product, Afrezza (inhalable insulin).

The FDA approved Afrezza on June 27, 2014.

On August 11, 2014 MannKind entered into an exclusive global licensing agreement with Sanofi for Afrezza sales. Under the agreement, MannKind received $150 million cash from Sanofi, in exchange for sharing profits and losses of sales of Afrezza, with 65% for Sanofi and 35% for MannKind. On January 5, 2016, MannKind Corporation announced the termination of the license and collaboration agreement with Sanofi. By December 2017, the company had lost 11% of its trading volume due to the poor sales.

In March 2020, the company announced it was working with fellow pharmaceutical company Immix Biopharma to try to develop an inhalable treatment for acute respiratory distress syndrome, a lung disease.

Products and product candidates

The firm has developed Afrezza a rapid-acting insulin peaking 12 to 15 minutes after inhalation and exiting the body within 2–3 hours. The inhalation technology uses a miniature, breath-powered inhaler in combination with single-use cartridges containing pre-metered doses. Initial pharmacokinetic studies were followed by studies of safety and efficiency involving Technosphere formulations of different therapeutic proteins.

Leadership

Mann was chief executive officer until January 12, 2015 when Hakan Edstrom became CEO and Mann transitioned to executive chairman.

In November 2015, Hakan Edstrom stepped down as CEO and president. Company founder Alfred Mann stepped in as interim CEO on November 19, 2015. In 2016, Matthew Pfeffer was appointed CEO of MannKind, and served as both CEO and CFO. In May 2017, Michael Castagna was named CEO of the company.

Facilities

MannKind has a large corporate office in Westlake Village, California. The Afrezza manufacturing facility is in Danbury, Connecticut. In 2022, the company moved its official headquarters to Danbury.

Leggi di più Mostra meno

Fonte: Wikipedia (Inglese), CC BY-SA 4.0 · Vedi su Wikipedia ↗

Wikidata ↗

settoreHealthcare industriaBiotechnology dipendenti591 paeseUS

Performance decennale Andamento di ricavi, utile netto, margini e EPS

06

Ricavi$349M

2016-12-31 → 2025-12-31

EPS$0.02

2016-12-31 → 2025-12-31

Flusso di cassa libero$14M

2018-12-31 → 2025-12-31

Margine netto-11.1%

2017-12-31 → 2025-12-31

Valutazione e Rapporti 07–12

Valutazione Rapporti P/E, P/S, P/B, EV/EBITDA — il titolo è costoso o economico?

Metrica	MNKD	media 5 anni	Mediana dei peer	Verdetto
P/E (TTM)	-29.4media 5 anni ≈45.5	≈45.5	·	·
P/S (TTM)	3.0media 5 anni ≈9.1	≈9.1	99.9	Sottovalutato
P/B (MRQ)	-17.6media 5 anni ≈-14.7	≈-14.7	·	·
Prezzo / FCF (TTM)	-65.3media 5 anni ≈7.7	≈7.7	·	·
Prezzo / Flusso di cassa (TTM)	-147.0media 5 anni ≈27.0	≈27.0	·	·
Prezzo / Valore contabile tangibile (MRQ)	-16.4	·	·	·

La mediana dei peer viene calcolata su base standardizzata per metrica e potrebbe non corrispondere sempre alla base TTM/MRQ mostrata per questo titolo.

Redditività Margini lordi, operativi e netti; ROE, ROA, ROIC

Metrica	MNKD	media 5 anni	Mediana dei peer	Verdetto
Margine Operativo (TTM)	2.3%media 5 anni ≈-17.1%	≈-17.1%	-431.2%	Di prim'ordine
EBITDA Margin (Margine EBITDA)	11.1%media 5 anni ≈-17.1%	≈-17.1%	-431.2%	Di prim'ordine
Margine ante imposte (TTM)	-12.4%media 5 anni ≈-37.8%	≈-37.8%	-451.0%	Di prim'ordine
Margine di Profitto Netto (TTM)	-11.1%media 5 anni ≈-37.9%	≈-37.9%	-392.7%	Di prim'ordine
ROA (TTM)	-7.6%media 5 anni ≈-12.4%	≈-12.4%	-57.7%	Di prim'ordine
ROE (TTM)	71.4%media 5 anni ≈10.3%	≈10.3%	-34.8%	Di prim'ordine
ROIC	-316.9%media 5 anni ≈-71.2%	≈-71.2%	-126.2%	Debole

Salute finanziaria Debito, liquidità, solvibilità — solidità del bilancio

Metrica	Tendenza 5 anni	MNKD	media 5 anni	Mediana dei peer	Verdetto
Rapporto corrente (MRQ)		1.7media 5 anni ≈3.3	≈3.3	11.6	Bassa liquidità
Quick Ratio (MRQ)		1.1media 5 anni ≈2.8	≈2.8	5.1	Bassa liquidità

Crescita Crescita di ricavi, EPS e utile netto: YoY, CAGR 3Y, CAGR 5Y

Metrica	MNKD	media 5 anni	Mediana dei peer	Verdetto
Revenue YoY (Ricavi YoY)	22.2%media 5 anni ≈42.6%	≈42.6%	·	·
Revenue CAGR 3Y (CAGR Ricavi 3Y)	51.8%media 5 anni ≈50.9%	≈50.9%	·	·
Revenue CAGR 5Y (CAGR Ricavi 5Y)	39.9%	·	·	·
EPS YoY	-80.0%	·	·	·
Net Income YoY (Utile Netto YoY)	-78.8%	·	·	·

Metriche per Azione EPS, valore contabile per azione, flusso di cassa per azione, dividendo per azione

Metrica	MNKD	media 5 anni	Mediana dei peer	Verdetto
EPS (Diluted) (EPS (Diluito))	$0.02media 5 anni ≈$-0.12	≈$-0.12	·	·
Revenue / Share (Ricavi / Azione)	$1.11media 5 anni ≈$0.81	≈$0.81	·	·
Cash Flow / Share (Flusso di cassa / Azione)	$0.06media 5 anni ≈$0.01	≈$0.01	·	·
Cash / Share (Liquidità / Azione)	$0.24media 5 anni ≈$0.41	≈$0.41	·	·

Efficienza del Capitale Rotazione delle attività, rotazione delle scorte, rotazione dei crediti

Metrica	MNKD	media 5 anni	Mediana dei peer	Verdetto
Asset Turnover (Rotazione delle attività)	0.6media 5 anni ≈0.5	≈0.5	0.2	Di prim'ordine
Inventory Turnover (Rotazione delle scorte)	0.8media 5 anni ≈1.2	≈1.2	·	·
Receivables Turnover (Rotazione dei crediti)	13.9media 5 anni ≈14.7	≈14.7	·	·
Revenue / Employee (Ricavi / Dipendente)	≈$590.5K	·	·	·

valore · ≈ media 5 anni · mediana del settore · giudizio rispetto alla mediana

Cronologia utili EPS effettivo vs stima, surprise %, tasso di superamento, data prossimi utili

14

Sorpresa media -86.3%

Prossimo report Nov 03, 2026

Periodo	Rapporto	EPS Actual	EPS Stimato	Sorpresa
30 Giugno 2026	Ago 12, 2026	$-0.06	$-0.00	—
31 Marzo 2026	Mag 13, 2026	$-0.05	$-0.00	—
31 Dicembre 2025		$-0.05	$0.01	-440.1%
30 Settembre 2025		$0.07	$0.02	205.9%
30 Giugno 2025		$0.00	$0.05	-100.0%
31 Marzo 2025		$0.04	$0.04	-10.9%

Fondamentali Completi Tutte le metriche per anno — conto economico, stato patrimoniale, rendiconto finanziario

15

Conto Economico 16

Metrica	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Revenue	$349M	$286M	$199M	$100M	$75M	$65M	$63M	$28M	$12M	$175M	$0	$0
Cost of Revenue	$27M	$17M	$21M	$16M	$17M	$15M	$20M	$19M	$17M	$17M	$65M	·
SG&A Expense	$144M	$94M	$94M	$91M	$32M	$25M	$75M	$80M	$75M	$47M	$41M	$79M
Operating Expenses	$88M	$77M	$63M	$57M	$39M	$25M	$108M	$104M	$120M	$107M	$345M	$180M
Operating Income	$39M	$73M	$9M	$-64M	$-47M	$-48M	$-45M	$-77M	$-108M	$67M	$-345M	$-180M
Interest Expense	·	·	$15M	$15M	$15M	·	·	·	·	·	$24M	$20M
Interest Income	$8M	$13M	$6M	$3M	$112.0K	$167.0K	$997.0K	$501.0K	$293.0K	$85.0K	$18.0K	$9.0K
Other Non-op	$-1M	$32.0K	$122.0K	$-102.0K	$-239.0K	$23.0K	$-926.0K	$-437.0K	$13.0K	$-597.0K	$1M	$2M
Pretax Income	$1M	$31M	$-10M	$-87M	$-81M	$-57M	$-52M	$-87M	$-117M	$126M	$-368M	$-198M
Income Tax	$-4M	$3M	$2M	$0	$0	$-218.0K	$0	$240.0K	$51.0K	$0	$0	$0
Net Income	$6M	$28M	$-12M	$-87M	$-81M	$-57M	$-52M	$-87M	$-117M	$126M	$-368M	$-198M
EPS (Basic)	$0.02	$0.10	$-0.04	$-0.34	$-0.32	$-0.26	·	$-0.60	$-1.13	$1.37	$-4.54	$-2.57
EPS (Diluted)	$0.02	$0.10	$-0.04	$-0.34	$-0.32	$-0.26	·	$-0.60	$-1.13	$1.36	$-4.54	$-2.57
Shares (Basic)	305,639,000	274,415,000	267,014,000	257,092,000	249,244,000	222,585,000	·	144,136,000	104,245,000	92,053,000	81,233,000	77,045,000
Shares (Diluted)	314,112,000	283,844,000	267,014,000	257,092,000	249,244,000	222,585,000	·	144,136,000	104,245,000	92,085,000	81,233,000	77,045,000
EBITDA	$39M	$73M	$9M	$-64M	$-47M	$-48M	$-45M	$-77M	$-106M	·	$-334M	$-170M

Stato Patrimoniale 28

Metrica	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Cash & Equivalents	$75M	$46M	$238M	$70M	$124M	$67M	$30M	$71M	$44M	$23M	$59M	$121M
Short-term Investments	$96M	$151M	$57M	$101M	$80M	$0	$20M	·	·	·	·	·
Receivables	$38M	$12M	$15M	$17M	$5M	$4M	$4M	$4M	$3M	$302.0K	$23.0K	$50M
Inventory	$35M	$28M	$29M	$22M	$7M	$5M	$4M	$4M	$3M	$2M	·	$10M
Prepaid Expense	$47M	$31M	$35M	$25M	$3M	$3M	$3M	$3M	$3M	$4M	$4M	$20M
Current Assets	$292M	$268M	$373M	$235M	$219M	$79M	$61M	$82M	$57M	$77M	$77M	$201M
PP&E (Net)	$82M	$85M	$84M	$45M	$37M	$26M	$27M	$26M	$27M	$29M	$49M	$192M
PP&E (Gross)	$196M	$192M	$186M	$144M	$134M	$123M	$122M	$126M	$128M	$129M	$168M	$310M
Accum. Depreciation	$114M	$107M	$102M	$99M	$98M	$97M	$95M	$100M	$101M	$100M	$120M	$118M
Goodwill	$68M	$2M	$2M	$2M	·	·	·	·	·	·	·	·
Intangibles	$5M	$5M	$1M	$1M	·	·	·	·	·	·	·	·
Other Non-current Assets	$20M	$27M	$7M	$10M	$8M	$3M	$6M	$249.0K	$437.0K	$648.0K	$1M	$848.0K
Total Assets	$792M	$394M	$475M	$295M	$321M	$109M	$94M	$108M	$85M	$107M	$126M	$394M
Accounts Payable	$9M	$7M	$10M	$11M	$7M	$6M	$5M	$5M	$7M	$3M	$16M	$7M
Accrued Liabilities	$65M	$40M	$42M	$36M	$27M	$20M	$16M	$15M	$12M	$8M	$8M	$26M
Short-term Debt	·	·	·	·	·	·	$5M	·	·	·	·	·
Current Liabilities	$171M	$82M	$104M	$67M	$48M	$74M	$66M	$75M	$88M	$92M	$268M	$403M
Capital Leases	$11M	$12M	$4M	$5M	$1M	$1M	$3M	·	·	·	·	·
Other Non-current Liabilities	·	·	·	·	$5M	·	·	·	·	·	$15M	$12M
Total Liabilities	$843M	$473M	$721M	$546M	$531M	$289M	$284M	$283M	$299M	$291M	$477M	$468M
Long-term Debt	$355M	$36M	$269M	$273M	$281M	$122M	$119M	$102M	$157M	·	·	·
Total Debt	·	·	·	·	·	·	$5M	·	·	·	·	·
Common Stock	$3M	$3M	$3M	$3M	$3M	$2M	$2M	$2M	$1M	$957.0K	$4M	$4M
Retained Earnings	$-3.20B	$-3.20B	$-3.23B	$-3.22B	$-3.13B	$-3.05B	$-2.99B	$-2.94B	$-2.85B	$-2.74B	$-2.86B	$-2.49B
AOCI	$115.0K	$1M	·	·	·	·	$-19.0K	$-19.0K	$-18.0K	$-24.0K	$-20.0K	$-14.0K
Stockholders' Equity	$-51M	$-79M	$-246M	$-251M	$-209M	$-180M	$-191M	$-175M	$-215M	$-184M	$-350M	$-74M
Liabilities + Equity	$792M	$394M	$475M	$295M	$321M	$109M	$94M	$108M	$85M	$107M	$126M	$394M
Shares Outstanding	307,832,587	302,959,782	270,034,495	263,793,305	251,477,562	242,117,089	211,787,573	187,029,967	119,053,414	95,680,831	85,734,188	406,059,089

Flusso di cassa 18

Metrica	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
D&A	$12M	$7M	$5M	$3M	$2M	$2M	$972.0K	$3M	$2M	$2M	$11M	$10M
Stock-based Comp	$24M	$21M	$18M	$13M	$12M	$7M	$6M	$7M	$5M	$5M	$9M	$49M
Deferred Tax	$-19M	$4M	$7M	$-10M	$-20M	$-5M	$-5M	$-11M	$-260M	$48M	$-80M	$-66M
Amort. of Intangibles	$4M	·	·	·	·	·	·	·	·	·	·	·
Restructuring	·	·	·	·	·	·	·	·	·	$2M	$6M	$2M
Other Non-cash	·	·	·	·	·	·	·	·	$306M	·	$291M	$144M
Operating Cash Flow	$18M	$43M	$34M	$-81M	$-62M	$-28M	$-88M	$-38M	$-65M	$-78M	$-57M	$4M
CapEx	$5M	$10M	$42M	$8M	$11M	$801.0K	$3M	$354.0K	·	$1M	$10M	$24M
Investing Cash Flow	$-305M	$-97M	$-2M	$5M	$-152M	$15M	$-23M	$-234.0K	$17M	$-1M	·	·
Debt Issued	·	·	·	·	·	$5M	·	·	·	·	·	$20M
Net Debt Issued	·	·	·	·	·	$5M	·	·	·	·	·	·
Stock Issued	·	·	·	·	·	·	·	·	$564.0K	$893.0K	$28M	·
Net Stock Activity	·	·	·	·	·	·	·	·	$564.0K	·	$28M	·
Financing Cash Flow	$315M	$-137M	$137M	$21M	$270M	$50M	$70M	$61M	$74M	$43M	·	·
Net Change in Cash	$29M	$-191M	$169M	$-54M	$57M	$37M	$-41M	$23M	$25M	$-36M	$-62M	$50M
Taxes Paid	$2M	$4M	·	·	·	·	·	·	·	·	·	·
Free Cash Flow	$14M	$33M	$-8M	$-88M	$-73M	$-29M	$-91M	$-38M	·	·	$-68M	$-20M
Levered FCF	·	·	$-26M	$-98M	·	·	·	·	·	·	$-92M	·

Redditività 7

Metrica	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Operating Margin	11.1%	25.4%	4.4%	-64.3%	-62.3%	-73.6%	-70.8%	-274.9%	-921.1%	·	·	·
Net Margin	1.7%	9.7%	-6.0%	-87.6%	-107.3%	-87.9%	-82.3%	-312.2%	-999.0%	·	·	·
Pretax Margin	0.40%	10.7%	-5.2%	-87.6%	-107.3%	-88.2%	-82.3%	-311.3%	-998.6%	·	·	·
EBITDA Margin	11.1%	25.4%	4.4%	-64.3%	-62.3%	-73.6%	-70.8%	-274.9%	-905.8%	·	·	·
ROA	0.99%	6.3%	-3.1%	-28.4%	-37.7%	-56.6%	-51.5%	-90.5%	-122.4%	·	-141.5%	-60.8%
ROE	-11.1%	-19.1%	4.8%	35.8%	41.1%	31.2%	27.7%	45.7%	58.9%	·	173.8%	379.7%
ROIC	-316.9%	-83.2%	-4.1%	25.6%	22.5%	26.5%	24.0%	43.9%	50.4%	·	98.4%	·

Liquidità e Solvibilità 4

Metrica	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Current Ratio	1.7	3.3	3.6	3.5	4.5	1.1	0.9	1.1	0.7	·	0.3	0.5
Quick Ratio	1.2	2.6	3.0	2.8	4.3	1.0	0.8	1.0	0.5	·	0.2	0.4
Debt / Equity	·	·	·	·	·	·	-0.0	·	·	·	·	·
Interest Coverage	·	·	0.6	-6.7	·	·	·	·	·	·	-14.3	-8.8

Efficienza 3

Metrica	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Asset Turnover	0.6	0.7	0.5	0.3	0.4	0.6	0.6	0.3	0.1	·	0.0	·
Inventory Turnover	0.8	0.6	0.8	1.1	2.8	3.3	5.2	6.2	6.9	·	·	·
Receivables Turnover	13.9	21.4	12.6	9.3	16.4	16.9	16.7	8.2	7.6	·	0.0	·

Per Azione 5

Metrica	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Book Value / Share	$-0.17	$-0.26	$-0.91	$-0.95	$-0.83	$-0.75	$-0.90	$-0.94	$-1.80	·	$-0.82	$-0.18
Revenue / Share	$1.11	$1.01	$0.75	$0.39	·	·	·	$0.19	$0.11	·	·	·
Cash Flow / Share	$0.06	$0.15	$0.13	$-0.31	·	·	·	$-0.26	$-0.62	·	·	·
Cash / Share	$0.24	$0.15	$0.88	$0.26	$0.49	$0.28	$0.14	$0.38	$0.37	·	$0.14	$0.30
EPS (TTM)	$0.02	$0.10	$-0.04	$-0.34	$-0.32	$-0.26	$-0.63	$-0.60	$-1.13	$1.36	$-4.54	$-2.57

Tassi di Crescita 5

Metrica	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Revenue YoY	22.2%	43.5%	99.4%	32.2%	15.8%	·	·	·	·	·	·	·
Revenue CAGR 3Y	51.8%	55.8%	45.1%	·	·	·	·	·	·	·	·	·
Revenue CAGR 5Y	39.9%	·	·	·	·	·	·	·	·	·	·	·
EPS YoY	-80.0%	·	·	·	·	·	·	·	·	·	·	·
Net Income YoY	-78.8%	·	·	·	·	·	·	·	·	·	·	·

Valutazione (TTM) 13

Metrica	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Revenue TTM	$349M	$286M	$199M	$100M	$75M	$65M	$63M	$28M	$12M	$175M	$0	$0
Net Income TTM	$6M	$28M	$-12M	$-87M	$-81M	$-57M	$-52M	$-87M	$-117M	$126M	$-368M	$-198M
Market Cap	$1.75B	$1.95B	$983M	$1.39B	$1.10B	$758M	$273M	$198M	$276M	·	$3.11B	$10.60B
Enterprise Value	·	·	·	·	·	·	$228M	·	·	·	·	·
P/E	283.5	64.3	-91.0	-15.5	-13.7	-12.0	-2.0	-1.8	-2.1	2.4	-1.6	-10.2
P/S	5.0	6.8	4.9	13.9	14.6	11.6	4.3	7.1	23.5	·	·	·
P/B	-34.2	-24.7	-4.0	-5.5	-5.2	-4.2	-1.4	-1.1	-1.3	·	-8.9	-143.7
P / Cash Flow	95.6	45.8	28.8	-17.2	-17.8	-26.9	-3.1	-5.3	-4.3	·	-54.3	2593.8
P / FCF	127.5	59.4	-117.8	-15.7	-15.0	-26.2	-3.0	-5.2	·	·	-46.0	-529.6
EV / EBITDA	·	·	·	·	·	·	-5.1	·	·	·	·	·
EV / FCF	·	·	·	·	·	·	-2.5	·	·	·	·	·
EV / Revenue	·	·	·	·	·	·	3.6	·	·	·	·	·
Earnings Yield	0.35%	1.6%	-1.1%	-6.5%	-7.3%	-8.3%	-48.8%	-56.6%	-48.7%	42.5%	-62.6%	-9.8%

Conto Economico 16

Metrica	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Revenue	$109M	$90M	$112M	$82M	$77M	$78M	$77M	$70M	$72M	$66M	$58M	$51M	$49M	$41M	$36M	$33M
Cost of Revenue	$14M	$8M	$14M	$4M	$5M	$4M	$5M	$3M	$6M	$4M	$6M	$4M	$5M	$6M	$4M	$5M
SG&A Expense	$58M	$54M	$58M	$29M	$32M	$25M	$24M	$24M	$24M	$22M	$61M	$11M	$12M	$11M	$64M	$9M
Operating Expenses	$30M	$92M	$-103M	$63M	$21M	$56M	$-86M	$57M	$56M	$50M	$18M	$14M	$14M	$16M	$16M	$17M
Operating Income	$-350.0K	$-2M	$-8M	$19M	$5M	$22M	$26M	$13M	$17M	$17M	$8M	$5M	$2M	$-6M	$-13M	$-10M
Interest Expense	·	·	·	·	·	·	·	·	$6M	$3M	·	$3M	$7M	$3M	·	$3M
Interest Income	$1M	$1M	$2M	$3M	$2M	$2M	$3M	$3M	$3M	$3M	$2M	$2M	$2M	$1M	$957.0K	$663.0K
Other Non-op	$-5M	$-3M	$23M	$-11M	$-4M	$-9M	$24M	$110.0K	$-18M	$-6M	$-164.0K	$318.0K	$-143.0K	$111.0K	$105.0K	$-207.0K
Pretax Income	$-19M	$-16M	$-21M	$8M	$940.0K	$14M	$8M	$13M	$-2M	$11M	$3M	$2M	$-5M	$-10M	$-18M	$-14M
Income Tax	$-106.0K	$253.0K	$-5M	$-204.0K	$272.0K	$459.0K	$1M	$1M	$323.0K	$264.0K	$2M	$0	$0	$0	·	$0
Net Income	$-19M	$-17M	$-16M	$8M	$668.0K	$13M	$7M	$12M	$-2M	$11M	$1M	$2M	$-5M	$-10M	$-18M	$-14M
EPS (Basic)	$-0.06	$-0.05	$-0.05	$0.03	$0.00	$0.04	$0.03	$0.04	$-0.01	$0.04	$0.01	$0.01	$-0.02	$-0.04	$-0.07	$-0.06
EPS (Diluted)	$-0.06	$-0.05	$-0.05	$0.03	$0.00	$0.04	$0.03	$0.04	$-0.01	$0.04	$0.01	$0.01	$-0.02	$-0.04	$-0.07	$-0.06
Shares (Basic)	309,191,000	308,267,000	·	306,806,000	304,954,000	303,481,000	·	274,998,000	273,056,000	270,356,000	·	268,732,000	265,626,000	263,969,000	·	259,300,000
Shares (Diluted)	309,191,000	308,267,000	·	311,638,000	311,484,000	320,897,000	·	284,693,000	273,056,000	324,733,000	·	323,770,000	265,626,000	263,969,000	·	259,300,000
EBITDA	·	$-2M	·	$19M	$5M	$22M	·	$13M	$17M	$17M	·	$5M	$2M	$-6M	·	$-10M

Stato Patrimoniale 25

Metrica	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Cash & Equivalents	$53M	$53M	$75M	$127M	$57M	$47M	$46M	$62M	$97M	$193M	·	$83M	$86M	$86M	·	$54M
Short-term Investments	$58M	$81M	$96M	$133M	$122M	$134M	$151M	$189M	$151M	$107M	·	$58M	$58M	$80M	·	$111M
Receivables	$43M	$28M	$38M	$17M	$27M	$29M	$12M	$18M	$23M	$20M	·	$22M	$28M	$20M	·	$23M
Inventory	$44M	$49M	$35M	$27M	$28M	$29M	$28M	$27M	$25M	$26M	·	$27M	$25M	$22M	·	$18M
Prepaid Expense	$47M	$40M	$47M	$54M	$44M	$34M	$31M	$31M	$30M	$36M	·	$36M	$33M	$15M	·	$12M
Current Assets	$246M	$251M	$292M	$359M	$279M	$274M	$268M	$328M	$326M	$383M	·	$226M	$230M	$223M	·	$218M
PP&E (Net)	$85M	$83M	$82M	$83M	$83M	$84M	$85M	$85M	$85M	$84M	·	$80M	$70M	$55M	·	$41M
PP&E (Gross)	$203M	$198M	$196M	$195M	$194M	$192M	$192M	$192M	$190M	$186M	·	$182M	$170M	$154M	·	$140M
Accum. Depreciation	$118M	$116M	$114M	$113M	$111M	$109M	$107M	$107M	$105M	$103M	·	$101M	$100M	$100M	·	$99M
Goodwill	$68M	$68M	$68M	$2M	$2M	$2M	$2M	$2M	$2M	$2M	·	$2M	$2M	$2M	·	$3M
Intangibles	$5M	$5M	$5M	$5M	$5M	$5M	$5M	$5M	$1M	$1M	·	$1M	$1M	$1M	·	$1M
Other Non-current Assets	$17M	$22M	$20M	$19M	$20M	$28M	$27M	$26M	$16M	$7M	·	$8M	$8M	$16M	·	$17M
Total Assets	$732M	$744M	$792M	$495M	$412M	$410M	$394M	$464M	$444M	$481M	·	$320M	$313M	$298M	·	$294M
Accounts Payable	$11M	$16M	$9M	$7M	$10M	$5M	$7M	$6M	$10M	$7M	·	$17M	$17M	$14M	·	$10M
Accrued Liabilities	$61M	$59M	$65M	$31M	$31M	$40M	$40M	$37M	$41M	$42M	·	$32M	$37M	$33M	·	$30M
Current Liabilities	$143M	$135M	$171M	$109M	$112M	$116M	$82M	$72M	$80M	$100M	·	$96M	$97M	$82M	·	$60M
Capital Leases	$10M	$10M	$11M	$10M	$11M	$11M	$12M	$12M	$3M	$4M	·	$4M	$5M	$5M	·	$6M
Total Liabilities	$800M	$804M	$843M	$539M	$467M	$469M	$473M	$674M	$670M	$711M	·	$572M	$574M	$554M	·	$532M
Long-term Debt	$319M	$319M	$355M	$110M	$36M	$36M	$36M	$228M	$228M	$264M	·	$273M	$274M	$274M	·	$273M
Common Stock	$3M	$3M	$3M	$3M	$3M	$3M	$3M	$3M	$3M	$3M	·	$3M	$3M	$3M	·	$3M
Retained Earnings	$-3.23B	$-3.21B	$-3.20B	$-3.18B	$-3.19B	$-3.19B	$-3.20B	$-3.21B	$-3.22B	$-3.22B	·	$-3.23B	$-3.23B	$-3.23B	·	$-3.20B
AOCI	$-19.0K	$-4.0K	$115.0K	$137.0K	$1M	$1M	$1M	$588.0K	·	·	·	$443.0K	$443.0K	·	·	$-1M
Stockholders' Equity	$-67M	$-59M	$-51M	$-45M	$-55M	$-59M	$-79M	$-210M	$-226M	$-230M	$-246M	$-252M	$-260M	$-255M	$-251M	$-238M
Liabilities + Equity	$732M	$744M	$792M	$495M	$412M	$410M	$394M	$464M	$444M	$481M	·	$320M	$313M	$298M	·	$294M
Shares Outstanding	309,911,682	308,907,331	307,832,587	307,027,189	306,332,133	303,918,969	302,959,782	275,775,038	274,467,247	270,801,781	·	269,543,539	268,235,145	264,278,760	·	263,156,165

Flusso di cassa 11

Metrica	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
D&A	$6M	$6M	$6M	$2M	$2M	$2M	$2M	$2M	$2M	$1M	$1M	$1M	$1M	$1M	$1M	$-427.0K
Stock-based Comp	$10M	$6M	$7M	$4M	$8M	$5M	$6M	$5M	$6M	$4M	$4M	$5M	$6M	$4M	$3M	$4M
Amort. of Intangibles	$4M	$4M	·	·	·	·	·	·	·	·	·	·	·	·	·	·
Operating Cash Flow	$-18M	$-5M	$-8M	$24M	$9M	$-6M	$23M	$9M	$4M	$7M	$22M	$9M	$3M	$1M	$-2M	$-28M
CapEx	$5M	$2M	$2M	$1M	$1M	$330.0K	$3M	$1M	$3M	$2M	$6M	$11M	$17M	$8M	$5M	$271.0K
Investing Cash Flow	$18M	$19M	$-292M	$-25M	$6M	$6M	$48M	$-41M	$-55M	$-48M	$-8M	$-12M	$4M	$14M	$15M	$27M
Financing Cash Flow	$559.0K	$-35M	$247M	$72M	$-6M	$1M	$-87M	$-2M	$-45M	$-3M	$142M	$-283.0K	$-6M	$1M	$3M	$20M
Net Change in Cash	$97.0K	$-22M	$-53M	$70M	$10M	$975.0K	$-16M	$-34M	$-96M	$-45M	$155M	$-3M	$315.0K	$16M	$15M	$19M
Taxes Paid	$753.0K	$63.0K	$549.0K	$80.0K	$869.0K	$207.0K	$2M	$236.0K	·	·	·	·	·	·	·	·
Free Cash Flow	·	$-7M	·	·	·	$-7M	·	·	·	$4M	·	·	·	$-7M	·	·
Levered FCF	·	·	·	·	·	·	·	·	·	$2M	·	·	·	$-10M	·	·

Redditività 7

Metrica	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Operating Margin	·	-1.8%	·	23.0%	6.9%	28.4%	·	18.2%	22.9%	25.2%	·	9.9%	3.5%	-14.8%	·	-29.3%
Net Margin	·	-18.4%	·	9.7%	0.87%	16.8%	·	16.5%	-2.8%	16.0%	·	3.4%	-10.8%	-24.1%	·	-44.0%
Pretax Margin	·	-18.1%	·	9.5%	1.2%	17.4%	·	18.4%	-2.3%	16.4%	·	3.4%	-10.8%	-24.1%	·	-44.0%
EBITDA Margin	·	-1.8%	·	23.0%	6.9%	28.4%	·	18.2%	22.9%	25.2%	·	9.9%	3.5%	-14.8%	·	-29.3%
ROA	·	-2.9%	·	1.7%	0.16%	2.9%	·	2.9%	-0.53%	2.7%	·	0.56%	-1.8%	-3.2%	·	-5.4%
ROE	·	28.2%	·	-6.3%	-0.48%	-9.1%	·	-5.0%	0.83%	-4.4%	·	-0.70%	2.1%	4.0%	·	6.8%
ROIC	·	2.9%	·	-43.5%	-6.8%	-36.8%	·	-5.5%	-8.8%	-7.1%	·	-2.0%	-0.66%	2.4%	·	·

Liquidità e Solvibilità 3

Metrica	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Current Ratio	·	1.9	·	3.3	2.5	2.4	·	4.5	4.1	3.8	·	2.3	2.4	2.7	·	3.7
Quick Ratio	·	1.2	·	2.5	1.8	1.8	·	3.7	3.4	3.2	·	1.7	1.8	2.3	·	3.2
Interest Coverage	·	·	·	·	·	·	·	·	2.7	6.5	·	1.8	0.3	-2.5	·	·

Efficienza 3

Metrica	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Asset Turnover	·	0.2	·	0.2	0.2	0.2	·	0.2	0.2	0.2	·	0.2	0.2	0.1	·	0.1
Inventory Turnover	·	0.2	·	0.2	0.2	0.1	·	0.1	0.2	0.2	·	0.2	0.2	0.4	·	0.4
Receivables Turnover	·	3.2	·	4.6	3.0	3.2	·	3.5	2.8	3.3	·	2.3	2.3	2.8	·	2.0

Per Azione 5

Metrica	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Book Value / Share	·	$-0.19	·	$-0.15	$-0.18	$-0.19	·	$-0.76	$-0.82	$-0.85	·	$-0.93	$-0.97	$-0.97	·	$-0.90
Revenue / Share	·	$0.29	·	$0.26	$0.25	$0.24	·	$0.25	$0.27	$0.20	·	$0.16	$0.18	$0.15	·	$0.13
Cash Flow / Share	·	$-0.02	·	·	·	$-0.02	·	·	·	$0.02	·	·	·	$0.00	·	·
Cash / Share	·	$0.17	·	$0.41	$0.19	$0.16	·	$0.23	$0.35	$0.71	·	$0.31	$0.32	$0.32	·	$0.21
EPS (TTM)	$-0.08	$-0.07	·	$0.10	$0.11	$0.10	·	$0.08	$0.05	$0.04	·	$-0.12	$-0.19	$-0.28	·	$-0.38

Valutazione (TTM) 8

Metrica	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Revenue TTM	$358M	$361M	·	$314M	$302M	$298M	·	$267M	$248M	$225M	·	$177M	$158M	$128M	·	$76M
Net Income TTM	$-27M	$-24M	·	$29M	$33M	$30M	·	$22M	$12M	$8M	·	$-31M	$-47M	$-71M	·	$-98M
Market Cap	·	$757M	·	$1.65B	$1.15B	$1.53B	·	$1.73B	$1.43B	$1.23B	·	$1.11B	$1.09B	$1.08B	·	$813M
P/E	-53.2	-35.0	·	53.7	34.0	50.3	·	78.6	104.4	113.2	·	-34.4	-21.4	-14.6	·	-8.1
P/S	·	2.1	·	5.3	3.8	5.1	·	6.5	5.8	5.5	·	6.3	6.9	8.4	·	10.7
P/B	·	-12.8	·	-37.0	-20.8	-26.1	·	-8.3	-6.3	-5.3	·	-4.4	-4.2	-4.2	·	-3.4
P / Cash Flow	·	-141.1	·	·	·	-239.7	·	·	·	183.0	·	·	·	937.3	·	·
Earnings Yield	-1.9%	-2.9%	·	1.9%	2.9%	2.0%	·	1.3%	0.96%	0.88%	·	-2.9%	-4.7%	-6.8%	·	-12.3%

Periodo più recente a sinistra · valori nulli mostrati come ·

Bilanci Conto economico, stato patrimoniale, flusso di cassa — annuale, ultimi 5 anni

16

Metrica	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Ricavi	$349M	$286M	$199M	$100M	$75M
Margine Operativo %	11.1%	25.4%	4.4%	-64.3%	-62.3%
Utile netto	$6M	$28M	$-12M	$-87M	$-81M
EPS Diluito	$0.02	$0.10	$-0.04	$-0.34	$-0.32

Metrica	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Rapporto corrente	1.7	3.3	3.6	3.5	4.5
Quick Ratio	1.2	2.6	3.0	2.8	4.3

Metrica	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Flusso di cassa libero	$14M	$33M	$-8M	$-88M	$-73M

Proprietari istituzionali (13F) 271 filer · $883.4M totale · Aggiornato al 30 Settembre 2026

17

Istituzioni che segnalano il possesso di questo titolo nel loro Modulo SEC 13F trimestrale. Solo posizioni lunghe; un singolo depositante può apparire due volte per diverse gambe di opzioni. Grandi posizioni put/call contrapposte riflettono tipicamente market-making o inventario coperto, non convinzione direzionale.

Detentori 271

Valore detenuto $883.4M

Nuove posizioni 51

Posizioni chiuse 39

Attività istituzionale — Q2 2026 vs trimestre precedente

Nuove posizioni	Posizioni chiuse	Aumentato	Diminuito	Variazione netta delle azioni
51 (0 vs trimestre precedente)	39 (-8 vs trimestre precedente)	98 (+12 vs trimestre precedente)	63 (-7 vs trimestre precedente)	+1.9M

Confrontato con Q1 2026. Le dichiarazioni SEC Form 13F sono dovute entro 45 giorni dalla fine del trimestre più un breve margine per i dichiaranti in ritardo — i trimestri ancora all'interno di questa finestra vengono saltati a favore della coppia più recente completamente riportata.

Istituzione	Valore	Azioni	% di 13F tracciati	Tipo
BlackRock, Inc.	$136.887.530	32.133.223	15,50%	Azioni
VANGUARD GROUP INC	$101.384.549	17.880.873	11,48%	Azioni
Rubric Capital Management LP	$76.680.000	18.000.000	8,68%	Azioni
STATE STREET CORP	$68.901.423	16.174.043	7,80%	Azioni
VANGUARD CAPITAL MANAGEMENT LLC	$56.101.610	13.169.392	6,35%	Azioni
GEODE CAPITAL MANAGEMENT, LLC	$33.861.886	7.947.203	3,83%	Azioni
WELLINGTON MANAGEMENT GROUP LLP	$33.418.878	7.844.807	3,78%	Azioni
Frazier Life Sciences Management, L.P.	$28.116.000	6.600.000	3,18%	Azioni
Deep Track Capital, LP	$25.560.000	6.000.000	2,89%	Azioni
180 WEALTH ADVISORS, LLC	$21.126.835	4.959.351	2,39%	Azioni
FMR LLC	$17.470.455	4.101.046	1,98%	Azioni
TSP Capital Management Group, LLC	$16.923.596	3.972.675	1,92%	Azioni
AQR CAPITAL MANAGEMENT LLC	$16.225.589	3.808.824	1,84%	Azioni
MORGAN STANLEY	$14.802.946	3.474.870	1,68%	Azioni
BRAIDWELL LP	$14.732.908	3.458.429	1,67%	Azioni
VANGUARD PORTFOLIO MANAGEMENT LLC	$12.789.240	3.002.169	1,45%	Azioni
NORTHERN TRUST CORP	$12.299.856	2.887.290	1,39%	Azioni
UBS Group AG	$12.295.344	2.886.231	1,39%	Azioni
TWO SIGMA INVESTMENTS, LP	$11.475.213	2.693.712	1,30%	Azioni
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	$11.070.577	2.598.727	1,25%	Azioni
BANK OF AMERICA CORP /DE/	$10.074.356	2.364.872	1,14%	Azioni
VANGUARD FIDUCIARY TRUST CO	$9.358.279	2.196.779	1,06%	Azioni
GOLDMAN SACHS GROUP INC	$9.178.165	2.154.499	1,04%	Azioni
WELLS FARGO & COMPANY/MN	$6.289.519	1.476.413	0,71%	Azioni
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$5.030.221	1.180.803	0,57%	Azioni
DIMENSIONAL FUND ADVISORS LP	$4.661.185	1.094.192	0,53%	Azioni
Caption Management, LLC	$4.260.000	1.000.000	0,48%	Opzione Put
Bank of New York Mellon Corp	$3.827.454	898.463	0,43%	Azioni
CITADEL ADVISORS LLC	$3.818.068	896.260	0,43%	Azioni
J. Goldman & Co LP	$3.478.669	816.589	0,39%	Azioni
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	$3.019.973	1.232.642	0,34%	Azioni
SCOPIA CAPITAL MANAGEMENT LP	$2.960.534	694.961	0,34%	Azioni
Balyasny Asset Management L.P.	$2.914.296	684.107	0,33%	Azioni
TWO SIGMA ADVISERS, LP	$2.897.166	510.964	0,33%	Azioni
VICTORY CAPITAL MANAGEMENT INC	$2.771.407	650.565	0,31%	Azioni
Nuveen, LLC	$2.708.218	635.732	0,31%	Azioni
Swiss National Bank	$2.502.324	587.400	0,28%	Azioni
STATE OF WISCONSIN INVESTMENT BOARD	$2.177.052	511.045	0,25%	Azioni
JACOBS LEVY EQUITY MANAGEMENT, INC	$2.106.540	494.493	0,24%	Azioni
1492 Capital Management LLC	$2.052.136	481.722	0,23%	Azioni
Mariner, LLC	$2.020.189	474.236	0,23%	Azioni
MILLENNIUM MANAGEMENT LLC	$1.836.597	431.126	0,21%	Azioni
Schonfeld Strategic Advisors LLC	$1.774.216	416.483	0,20%	Azioni
Squarepoint Ops LLC	$1.759.644	413.062	0,20%	Azioni
Jefferies Financial Group Inc.	$1.694.202	397.700	0,19%	Azioni
ExodusPoint Capital Management, LP	$1.666.261	391.141	0,19%	Azioni
JANE STREET GROUP, LLC	$1.658.418	389.300	0,19%	Opzione Call
PRINCIPAL FINANCIAL GROUP INC	$1.629.561	382.526	0,18%	Azioni
Man Group plc	$1.624.023	381.226	0,18%	Azioni
RHUMBLINE ADVISERS	$1.604.647	376.681	0,18%	Azioni

Mostra tutti i 271 proprietari istituzionali →

Attivisti e proprietari del 5%+ 2 partecipazioni

18

Investitori che hanno depositato SEC Schedule 13D — proprietà effettiva superiore al 5% con l'intento di influenzare l'emittente (partecipazioni attiviste, campagne per il consiglio di amministrazione, M&A). Ogni riga mostra lo stato più recente noto della posizione di quel depositante.

Depositante	Depositato	Partecipazione	Stato	Scopo	Deposito
Alfred E. Mann, Alfred E. Mann Living Trust, Biomed Partners, LLC, Minimed Infusion, Inc., The Mann Group LLC ×2 depositi	10 Luglio 2012	·	Deposito iniziale	Investimento passivo	SEC
Persona segnalante non divulgata, Persona segnalante non divulgata, Persona segnalante non divulgata, Persona segnalante non divulgata	31 Gennaio 2006	·	Deposito iniziale	·	SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Insider aziendali 43 insider · 27 dirigenti · 19 direttori

19

Insider	Ruolo	Ultima attività	Azioni possedute	Acquisti 12m	Vendite 12m	Netto 12m
Michael Castagna	Chief Executive Officer	15 Luglio 2026 M	2.433.779	1	4	$-990.292
Hakan Edstrom	President & CEO	27 Agosto 2015 A	1.114.340	0	0	$0
Christopher B Prentiss	Chief Financial Officer	15 Luglio 2026 F	318.668	0	0	$0
Juergen Martens	Corporate VP and COO	27 Agosto 2015 A	106.539	0	0	$0
Dominic Marasco	Pres, Endocrine Business Unit	15 Luglio 2026 F	343.398	0	0	$0
Sanjay R Singh	EVP Technical Operations	15 Luglio 2026 M	478.966	0	1	$-94.448
Stuart A Tross	Chief People & Workpl Officer	15 Luglio 2026 M	1.058.142	0	1	$-297.548
David Thomson	EVP Genl Counsel & Secretary	15 Luglio 2026 M	797.554	0	3	$-930.755
Ajay Ahuja	Chief Medical Officer	23 Marzo 2026 A	318.200	0	0	$0
Lauren M Sabella	EVP Operations	15 Luglio 2025 F	349.841	0	0	$0
Burkhard Blank	EVP Chief Medical Officer	15 Luglio 2025 F	460.791	0	0	$0
Joseph Kocinsky	Chief Technology Officer	27 Agosto 2022 F	745.233	0	0	$0
Alejandro Galindo	EVP Endocrine Business Unit	28 Febbraio 2022 A	576.690	0	0	$0
Rosabel Realica Alinaya	VP, IR & Treasury	27 Agosto 2020 A	167.119	0	0	$0
David M Kendall	Chief Medical Officer	31 Luglio 2020 P	41.059	0	0	$0
Patrick Mccauley	Chief Commercial Officer	25 Febbraio 2020 A	83.972	0	0	$0
Courtney Barton	Chief Compl & Privacy Officer	31 Luglio 2019 P	29.584	0	0	$0
Elizabeth Garrett Ingram	Chief Marketing Officer	14 Maggio 2019 A	43.012	0	0	$0
Raymond W. Urbanski	Corp VP, CMO	10 Agosto 2017 S	2.924	0	0	$0
Linda A Adreveno	Sr. VP, HR	18 Febbraio 2016 A	92.200	0	0	$0
Alfred E Mann	Executive Chairman	22 Agosto 2015 F	1.005.990	0	0	$0
Diane Palumbo	Vice President, Human Resource	23 Febbraio 2015 F	50.624	0	0	$0
Peter C Richardson	Chief Scientific Officer	03 Marzo 2012 F	133.611	0	0	$0
Richard L Anderson	Corporate VP	16 Novembre 2008 F	204.401	0	0	$0
John R. Riesenberger	VP & Chief Commercial Officer	13 Agosto 2008 A	14.650	0	0	$0
Dan Burns	VP & President, MKBP	08 Dicembre 2006 A	14.800	0	0	$0
Wendell W Cheatham	VP, Medical & Reg Affairs	19 Agosto 2004 A	300	0	0	$0
Steven B. Binder	Direttore	25 Settembre 2026 S	713.258	0	5	$-683.703
Sabrina Kay	Direttore	20 Maggio 2026 A	265.600	0	0	$0
Jennifer Grancio	Direttore	20 Maggio 2026 A	244.815	0	0	$0
James Samuel Shannon	Direttore	20 Maggio 2026 A	64.635	0	0	$0
Michael A Friedman	Direttore	20 Maggio 2026 A	47.500	0	0	$0
Anthony C Hooper	Direttore	20 Maggio 2026 A	236.153	0	0	$0
Christine Mundkur	Direttore	20 Maggio 2026 A	254.493	0	0	$0
Ronald J Consiglio	Direttore	20 Maggio 2026 A	132.342	0	0	$0
Kent Kresa	Direttore	15 Maggio 2024 A	274.541	0	0	$0
Henry L Nordhoff	Direttore	14 Maggio 2019 A	103.426	0	0	$0
David Maccallum	Direttore	16 Maggio 2018 A	114.790	0	0	$0
Matthew J Pfeffer	Direttore	28 Agosto 2017 F	81.961	0	0	$0
Abraham E Cohen	Direttore	17 Agosto 2012 S	56.424	0	0	$0
Heather Hay Murren	Direttore	13 Agosto 2008 A	10.100	0	0	$0
Kathleen Connell	Direttore	25 Maggio 2006 A	·	0	0	$0
Llew Keltner	Direttore	25 Maggio 2006 A	·	0	0	$0

Insider dai depositi SEC Modulo 3/4/5; netto = solo acquisti/vendite di mercato

Proprietà ETF Posseduti da 29 ETF

20

Il peso riflette solo le partecipazioni azionarie dirette (N-PORT); fondi a leva o basati su derivati possono detenere ulteriore esposizione swap non mostrata.

Fondo	Peso	Unità	Aggiornato al	Fonte
JSMD · Janus Detroit Street Trust	0,62%	1.678.187 NS	31 Luglio 2026	N-PORT
QQQS · Invesco Exchange-Traded Fund Trust …	0,52%	29.891 SH	02 Ottobre 2026	Giornaliero
JSML · Janus Detroit Street Trust	0,49%	450.643 NS	31 Luglio 2026	N-PORT
FYC · First Trust Exchange-Traded AlphaDE…	0,37%	1.212.660 NS	31 Luglio 2026	N-PORT
LABU · Direxion Shares ETF Trust	0,23%	289.432 NS	31 Luglio 2026	N-PORT
FYX · First Trust Exchange-Traded AlphaDE…	0,12%	409.547 NS	31 Luglio 2026	N-PORT
IBBQ · Invesco Exchange-Traded Fund Trust …	0,09%	22.737 SH	02 Ottobre 2026	Giornaliero
IBB · iShares Trust	0,08%	2.264.902 SH	11 Settembre 2026	Giornaliero
VTWG · VANGUARD SCOTTSDALE FUNDS	0,08%	330.117 SH	19 Agosto 2026	Giornaliero
IWO · iShares Trust	0,08%	2.877.921 SH	11 Settembre 2026	Giornaliero
FAD · First Trust Exchange-Traded AlphaDE…	0,07%	109.855 NS	31 Luglio 2026	N-PORT
PWS · Pacer Funds Trust	0,06%	3.954 NS	31 Luglio 2026	N-PORT
ESML · iShares Trust	0,05%	333.357 SH	11 Settembre 2026	Giornaliero
VTWO · VANGUARD SCOTTSDALE FUNDS	0,04%	1.771.496 SH	19 Agosto 2026	Giornaliero
RSSL · Global X Funds	0,04%	147.059 NS	31 Luglio 2026	N-PORT
ISCG · iShares Trust	0,04%	96.772 SH	11 Settembre 2026	Giornaliero
IWM · iShares Trust	0,04%	7.845.946 SH	11 Settembre 2026	Giornaliero
VHT · VANGUARD WORLD FUND	0,02%	874.372 SH	19 Agosto 2026	Giornaliero
FHLC · FIDELITY COVINGTON TRUST	0,02%	139.696 NS	31 Luglio 2026	N-PORT
VXF · VANGUARD INDEX FUNDS	0,01%	3.543.398 SH	19 Agosto 2026	Giornaliero
WSML · iShares Trust	0,01%	16.637 SH	11 Settembre 2026	Giornaliero
TILT · FlexShares Trust	0,00%	23.700 NS	31 Luglio 2026	N-PORT
ITOT · iShares Trust	0,00%	465.405 SH	11 Settembre 2026	Giornaliero
IWV · iShares Trust	0,00%	84.120 SH	10 Settembre 2026	Giornaliero
DFAC · Dimensional ETF Trust	0,00%	58.407 NS	31 Luglio 2026	N-PORT
DFAS · Dimensional ETF Trust	0,00%	11.291 NS	31 Luglio 2026	N-PORT
VTI · VANGUARD INDEX FUNDS	0,00%	9.327.332 SH	19 Agosto 2026	Giornaliero
VTHR · VANGUARD SCOTTSDALE FUNDS	0,00%	26.184 SH	19 Agosto 2026	Giornaliero
ISCB · iShares Trust	·	13.557 SH	11 Settembre 2026	Giornaliero

MNKD Consenso degli analisti Opinioni degli analisti, sia rialziste che ribassiste, target price a 12 mesi, potenziale di rialzo

21

rating · 14 analisti COMPRA

Target mediano $7.50 +96,3%

4 28,6% Acquisto forte

8 57,1% Compra

2 14,3% Mantieni

0 0,0% Vendi

0 0,0% Vendita forte

Target Price a 12 Mesi

8 analisti · 2026-10-05

Target medio $7.97 +108,6%

← Sotto tutti i target Prezzo attuale $3.82

Basso$4.75 Media$7.97 Alto$13.00

Confronto Peer (GICS sub-settore industriale) Metriche chiave rispetto ai pari del settore

22

Base FY, prezzi alla chiusura dell'ultimo anno fiscale di ciascuna società.

Ticker	Capitalizzazione di Mercato	P/E	Rev YoY	Margine Netto	ROE	Margine lordo
MNKD	$1.75B	283.5	22.2%	1.7%	-11.1%	·
INBX	$1.15B	-8.7	550.0%	-10773.5%	-365.9%	·
ORIC	$806M	-5.6	·	·	-36.5%	·
DMRA	·	·	38.3%	-17981.1%	-167.0%	·
REPL	$633M	-2.3	·	·	-146.2%	·
TRAX	·	·	·	·	·	·
BCAX	$953M	-6.7	·	·	-33.0%	·
VOR	$506M	-0.2	·	·	83.4%	·
MGTX	$645M	-5.6	144.6%	-140.3%	8062.2%	·

Ultime notizie Notizie recenti che menzionano questa società

23

Wells Fargo Calls MannKind Corporation (MNKD)’s Commercial Potential a “Show-Me Story” Yahoo Finance · 3 mesi, 3 settimane fa MannKind (MNKD) Advances Clinical Trials for Inhaled IPF Therapy Yahoo Finance · 3 mesi, 4 settimane fa H.C. Wainwright e Wells Fargo Aumentano i Price Target di MannKind (MNKD) Yahoo Finance · 4 mesi, 3 settimane fa MannKind Corporation (MNKD) è una delle popolari penny stock su Robinhood da acquistare? Yahoo Finance · 6 mesi fa

Segnali di trading Segnali recenti di acquisto/vendita con prezzo di entrata e rapporto rischio/rendimento

25

BOUNCE_UP Stop out Dic 23

rischio 1 premio 2,00

ingresso $5.89 R:R 2,00

Nessun segnale aperto al momento — nessuna scheda è compilata, e questo è onesto.

Le Mie Metriche La tua watchlist personale — righe selezionate da Fondamentali Completi

26

Scegli le metriche che contano per te: fai clic sul + accanto a qualsiasi riga in Fondamentali Completi sopra.

La tua selezione è salvata e ti segue su tutti i ticker.

MNKD MannKind Corporation - Common Stock